Using New Antipsychotics in Your Clinical Practice

During a recent teleconference, four experts on the treatment of schizophrenia discussed “Challenges and Solutions in the Development of New Agents for the Treatment of Schizophrenia.” Below is an interactive audio-visual report of the teleconference, including seven different illustrated excerpts from the discussion presenting the doctors' recommendations on using new antipsychotics.


See also Academic Highlights: Challenges and Solutions in Developing New Medications for Schizophrenia

<object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase=",0,0,0" width="600" height="600" id="loader2" align="middle"> <param name="allowScriptAccess" value="sameDomain"> <param name="movie" value="/education/documents/loader2.swf"> <param name="quality" value="high"> <param name="bgcolor" value="#000000"> <embed src="/education/documents/loader2.swf" quality="high" bgcolor="#000000" width="600" height="600" name="loader2" align="middle" allowscriptaccess="sameDomain" type="application/x-shockwave-flash" pluginspage=""> </object>

Assessment Tools

Practical Tools for Assessing Response in Clinical Settings

The UCSD Performance-Based Skills Assessment (UPSA-Brief) Administration & Scoring Manual

Additional Materials

Take Home Points from the Teleconference

References for “Practical Tools for Assessing Response in Clinical Settings”

Academic Highlights: Challenges and Solutions in Developing New Medications for Schizophrenia

This report presents the highlights of a roundtable teleconference on “Using New Antipsychotics in Your Clinical Practice” which was held in January 2010. This report was prepared by Healthcare Global Village, Inc., and was supported by an educational grant from Dainippon Sumitomo Pharma America, Inc/Sepracor. The teleconference was chaired by Steven G. Potkin, M.D., Department of Psychiatry and Human Behavior and UCI Brain Imaging Center, University of California, Irvine. The faculty were Adrian Preda, M.D., Department of Psychiatry and Human Behavior, University of California, Irvine; Amir H. Kalali, M.D., Quintiles, Inc., and Department of Psychiatry, University of California, San Diego; and Philip D. Harvey, Ph.D., Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL

Financial disclosure: Dr Potkin has grant, advisory board, and speakers bureau financial relationships with the following companies: Bioline, Bristol-Myers Squibb, Cortex, Dainippon Sumitomo/Sepracor, Elan, Eli Lilly, Forest, Janssen, Merck/Schering Plough, Minster, Novartis, Otsuka, Pfizer/Wyeth, Solvay, and Roche. Dr Harvey is a consultant for Eli Lilly, Solvay, Shire, DSPA, and Merck and has received grant/research support from AstraZeneca. Dr. Kalali has grant, advisory board, and speakers bureau financial relationships with the following companies: AstraZeneca, Merck, Novartis, Pfizer, and Takeda. He is also on the board of directors of Cypress Biosciences. Dr. Preda has nothing to disclose.

Financial support: This report was funded by a grant from Sunovion Pharmaceuticals. Project management was provided by Healthcare Global Village, Inc. The faculty acknowledges Ruth Ross, Project Manager, Healthcare Global Village, for her assistance in developing the report. The opinions expressed in this report are those of the faculty and do not necessarily reflect the views of Healthcare Global Village, Inc., Physicians Postgraduate Press, Inc., or the commercial supporter.


1. Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol 2009;12:1233-1248

2. Bowie CR, Leung WW, Reichenberg A, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 2008;63:505-511

3. Leifker FR, Bowie CR, Harvey PD. Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms. Schizophr Res 2009;115:82-87

4. Harvey PD. Is it possible to assess cognitive impairment other than with neuropsychological tests? Psychiatry (Edgmont) 2009;6:23–25

5. Harvey PD. Direct measurement of disability. Psychiatry (Edgmont) 2009;6:43–46

6. Harvey PD, Penn D. Social cognition: The key factor predicting social outcome in people with schizophrenia? Psychiatry (Edgmont). 2010; 7: 41–44.

7. Patterson TL, Goldman S, McKibbin CL, et al. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27:235–245.

8. Velligan DI, Diamond P, Glahn DC, et al. The reliability and validity of the test of adaptive behavior in schizophrenia. Psychiatry Res. 2007;151:55–66.

9. Mausbach BT, Harvey PD, Goldman SR, et al. Initial development and validation of the Brief UCSD Performance-based Skills Assessment. Schizophr Bull. 2007;33:1364–1372.

10. Bowie CR, Twamley EW, Anderson H, et al. Self-assessment of functional status in schizophrenia. J Psychiatr Res. 2007;41:1012–1018.

11. McGurk SR, Mueser KT, Feldman K, et al. Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry 2007;164:437–441

12. Vinogradov S, Fisher M, Holland C, et al. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 2009;66:549-553

13. Scharfman H, Goodman J, Macleod A, et al. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 2005;192:348-356

14. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci 2003;91:267-270

15. Penn DL, Combs D. Modification of affect perception deficits in schizophrenia. Schizophr Res 2000;46:217–229

16. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166:141–147

17. Combs DR, Elerson K, Penn DL, et al. Stability and generalization of Social Cognition and Interaction Training (SCIT) for schizophrenia: six-month follow-up results. Schizophr Res. 2009;112:196–197.

18. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70:801-809